Breaking News, Collaborations & Alliances

Charles River & Rznomics Partner to Initiate Clinical Development of RZ-001

Partnership will provide adenoviral vector production enabling initiation of clinical trials.

Author Image

By: Charlie Sternberg

Associate Editor

Charles River Laboratories International Inc. and Rznomics Inc., a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, have announced a viral vector contract development and manufacturing organization (CDMO) partnership.   Rznomics will leverage Charles River’s viral vector CDMO experience to initiate clinical development of its RNA-based anticancer gene therapy in liver cancer patients.   RZ-001 is the first ribozyme-based RNA reprogram...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters